Clinical trial
Use of Serum Bilirubin/Albumin Ratio for Early Prediction of Bilirubin Induced Neurological Dysfunction
NCT06603753 is registered in ClinicalTrials.gov with alaa aboelhassan mohamed aboelhassan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of Serum Bilirubin/Albumin Ratio for Early Prediction of Bilirubin Induced Neurological Dysfunction
- Lead sponsor
- alaa aboelhassan mohamed aboelhassan
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 1, 2025
- Completion date
- July 1, 2026
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.